|Dr. Michael E. Castagna Pharm.D.||Chief Exec. Officer, Chief Commercial Officer & Director||378.41k||N/A||40|
|Dr. David B. Thomson Ph.D., J.D.||Corp. VP, Gen. Counsel and Corp. Sec.||458.68k||424.8k||50|
|Dr. Raymond W. Urbanski M.D., Ph.D.||Chief Medical Officer and Corp. VP||501.32k||N/A||58|
|Ms. Rosabel Realica Alinaya||Acting Chief Financial Officer, Principal Accounting Officer and Sr. VP of Fin.||N/A||N/A||56|
|Mr. Joseph Kocinsky||Chief Technology Officer and Corp. VP of Technical Operations||N/A||N/A||53|
MannKind Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic products for diabetes diseases in the United States. Its approved product is Afrezza, a rapid-acting, inhaled insulin used to control high blood sugar in adults with type 1 and type 2 diabetes. The company was founded in 1991 and is headquartered in Valencia, California.
MannKind Corporation’s ISS Governance QualityScore as of June 2, 2017 is 5. The pillar scores are Audit: 10; Board: 5; Shareholder Rights: 4; Compensation: 5.